Phase I/II Trial of Dasatinib (Sprycel) With Radiation Therapy and Concomitant and Adjuvant Temozolomide in Patients With Newly-Diagnosed Glioblastoma.

Trial Profile

Phase I/II Trial of Dasatinib (Sprycel) With Radiation Therapy and Concomitant and Adjuvant Temozolomide in Patients With Newly-Diagnosed Glioblastoma.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 01 Feb 2016

At a glance

  • Drugs Dasatinib (Primary) ; Temozolomide
  • Indications Glioblastoma; Gliosarcoma
  • Focus Adverse reactions
  • Most Recent Events

    • 10 Sep 2013 Status changed from active, no longer recruiting to discontinued as reported by M.D. Anderson Cancer Center.
    • 26 Feb 2013 Planned End Date changed from 1 May 2013 to 1 May 2014 as reported by ClinicalTrials.gov.
    • 01 Nov 2011 Planned end date changed from 1 May 2012 to 1 May 2013.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top